Verhagen, Johan http://orcid.org/0000-0001-8414-1342
Smith, Emma L.
Whettlock, Emily M.
Macintyre, Benedict
Peakman, Mark
Funding for this research was provided by:
The work was funded by UCB Pharma Ltd
Article History
Received: 29 June 2018
Accepted: 7 September 2018
First Online: 20 September 2018
Competing Interests
: J.V., E.W., B.M. declare no financial or non-financial conflicts of interest. E.S. is an employee of UCB Pharma Ltd. who are developing peptide immunotherapy for type 1 diabetes. M.P. is employed by King’s College London, which has a licence agreement in place with UCB Pharma to develop peptide immunotherapy. M.P. receives research funds and honoraria from UCB.